

Qiang Shen, MD, PhD
Professor

Education

Jiangxi Medical College, Shangrao, Jiangxi, China	Diploma of Medicine	1981	Medicine
Guangfeng County Hospital, Guangfeng, Jiangxi, China	Residency	1986	Medicine, Gen. Surgery
Fujian Medical University First Teaching Hospital, Quanzhou, Fujian, China	Residency	1984	Medicine, Gen. Surgery
Kunming Medical University, Kunming, Yunnan, China	M.D., M.S.	1989	Medicine, Gen. Surgery
University of Texas Medical Branch, Galveston, TX	Ph.D.	2001	Cell Biology
Baylor College of Medicine, Houston, TX	Postdoc	2006	Cancer Biology & Cancer Prevention



Dr. Qiang Shen is a professor in the department of interdisciplinary oncology. He has a broad background in medicine and cancer biology research, with specific training and expertise in breast cancer biology and cell biology, cancer prevention, metastasis, targeted anticancer drug development, histology and pathology, and animal models of human cancers.

Dr. Shen received medical degrees from Jiangxi Medical College and Kunming Medical University, and practiced medicine as a physician surgeon in China. Dr. Shen then obtained his Ph.D. degree in Cell Biology from the University of Texas Medical Branch at Galveston. After completion of his postdoctoral training at Baylor College of Medicine, Dr. Shen was promoted to Instructor positions at Baylor.

Dr. Shen was recruited as tenure-track assistant professor to The University of Texas M.D. Anderson Cancer Center in 2009 and promoted as associate professor with tenure in 2017, before he joined LSU Health Science Center as professor in 2019.

Patents

1. Novel Small-Molecule STAT3 Inhibitors for Cancer Prevention and Therapy, United States, UTMB Galveston/MD Anderson Cancer Center, J. Zhou, H. Chen, and Q. Shen. US 61/752,866, 01/15/2013. International Publication No. WO 2014/113467 A1.
2. Oridonin Analogs, Compositions, and Methods Related Thereto, United States, UTMB Galveston/MD Anderson Cancer Center, J. Zhou, C. Ding, and Q. Shen. US 61/808,753,

04/05/2013. PCT WO 2014/165841 A1. US Patent No.: US 10,072,022 B2. Date of Patent: 09/11/2018.

3. HIPK Inhibitors and Methods of Use Thereof. United States, MD Anderson Cancer Center/Vibliome Inc., Q. Shen, G. Flynn. US 62/807,594; filed 02/19/2019.